Tarsus Pharmaceuticals financials
$76.69−0.16%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M | $0.00 |
| Gross profit | $420.7M | $170.1M | $15.9M | $24.9M | $55.0M | $0.00 |
| Gross margin | 93.2% | 93.0% | 90.9% | 96.3% | 96.4% | — |
| Operating income | -$71.0M | -$120.6M | -$143.2M | -$62.7M | -$12.2M | -$27.0M |
| Net income | -$66.2M | -$115.4M | -$135.8M | -$62.1M | -$13.8M | -$26.8M |
| Net margin | −14.7% | −63.1% | −778.5% | −240.5% | −24.2% | — |
| Diluted EPS | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-4.32 |
| EBITDA | -$74.6M | -$123.6M | -$145.4M | -$62.4M | -$11.8M | -$26.9M |
| Operating cash flow | -$12.5M | -$83.0M | -$117.5M | -$49.0M | $3.7M | -$21.1M |
| Free cash flow | -$22.3M | -$84.6M | -$119.0M | -$49.5M | $3.2M | -$21.6M |
| Diluted shares | 41.8M | 37.6M | 29.4M | 24.6M | 20.6M | 6.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $183.6M | $94.8M | $224.9M | $71.7M | $171.3M | $168.1M |
| Short-term investments | $233.6M | $196.6M | $2.5M | $145.4M | $483.0K | $0.00 |
| Total debt | $72.4M | $71.8M | $29.8M | $19.4M | $0.00 | $0.00 |
| Total assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M | $172.0M |
| Total liabilities | $218.7M | $152.5M | $68.5M | $35.0M | $12.2M | $6.0M |
| Shareholders' equity | $343.4M | $224.5M | $197.0M | $192.9M | $166.7M | $166.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology